Regulated expression of a dominant negative protein kinase C epsilon mutant inhibits the proliferation of U-373MG human astrocytoma cells.
The tight regulation of protein kinase C (PKC) activity is crucial for maintaining normal cell proliferation. Excessive PKC activity leads to uncontrolled growth and malignant transformation. It has been reported that the activity of PKC is higher in astroglial cell lines than in normal astrocytes. Previously, we demonstrated that PKC epsilon is overexpressed in astroglial cell lines and in samples from primary high-grade astroglial brain tumors. Because there are no PKC epsilon isozyme-specific inhibitors, we chose a genetic approach to confirm that PKC epsilon is a potential target for inhibiting astroglial cell proliferation. We regulated the expression of a dominant negative PKC epsilon mutant (PKC epsilon 1-401 encoding amino acid 1-401) in U-373MG human astrocytoma cells using a tetracycline-regulated expression vector and established stable clones. Induction of expression of the dominant negative PKC epsilon mutant by the addition of doxycycline, a tetracycline derivative, completely blocked proliferation of U-373MG cells in proliferation and clonogenic assays. Although the induction of the dominant negative PKC epsilon mutant did not markedly affect mitogen-induced tyrosine phosphorylation of the mitogen-activated protein (MAP) kinases, it inhibited the induction of c-Fos protein expression by substance P (SP) and fetal bovine serum (FBS). These results clearly show that the expression of dominant negative PKC epsilon leads to the inhibition of U-373MG cellular proliferation demonstrating that this isozyme may be a potential therapeutic target for astroglial brain tumors.
Department of Molecular Pharmacology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
T R
TR
Sharif
N
N
Sasakawa
M
M
Sharif
D000818:Animals; D001254:Astrocytoma / Q000201:enzymology* / Q000235:genetics* / Q000473:pathology; D002417:Cattle; D002455:Cell Division / Q000235:genetics; D004790:Enzyme Induction / Q000235:genetics; D005312:Fetal Blood / Q000502:physiology; D015971:Gene Expression Regulation, Enzymologic / Q000502:physiology*; D005799:Genes, Dominant / Q000502:physiology; D006131:Growth Inhibitors / Q000096:biosynthesis / Q000235:genetics* / Q000502:physiology; D006801:Humans; D007527:Isoenzymes / Q000096:biosynthesis / Q000235:genetics* / Q000502:physiology; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism; D009154:Mutation / Q000235:genetics*; D010766:Phosphorylation; D011493:Protein Kinase C / Q000096:biosynthesis / Q000235:genetics* / Q000502:physiology; D051744:Protein Kinase C-epsilon; D016760:Proto-Oncogene Proteins c-fos / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000502:physiology; D013373:Substance P / Q000502:physiology; D014407:Tumor Cells, Cultured
D006131:Growth Inhibitors; D007527:Isoenzymes; D016760:Proto-Oncogene Proteins c-fos; D013373:Substance P; C497255:PRKCE protein, human; D011493:Protein Kinase C; D051744:Protein Kinase C-epsilon; D020928:Mitogen-Activated Protein Kinases